TY - JOUR
T1 - Childhood rhabdomyosarcoma xenografts
T2 - Responses to DNA-interacting agents and agents used in current clinical therapy
AU - Houghton, Janet A.
AU - Cook, Ruby L.
AU - Lutz, Pamela J.
AU - Houghton, Peter J.
N1 - Funding Information:
Accepted 27 December 1983. *Supported by Grant CH-156 from the American Society, CA 25099 from the National Cancer Institute ALSAC.
PY - 1984/7
Y1 - 1984/7
N2 - A laboratory model of childhood rhabdomyosarcoma (RMS) has been used to evaluate cytotoxic agents used in current clinical protocols, and DNA-reacting agents that have had either limited or no evaluation in this histiotype. Seven lines of RMS each derived from a different patient were grown as xenografts in immune-deprived mice, six of these being from specimens derived from previously untreated patients. Of the 'conventional' agents, vincristine was the most effective. Of the other agents evaluated [L-phenylalanine mustard (L-PAM), cis-dichlorodiammineplatinum (cis-DDP), mitomycin C and 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC)], L-PAM caused complete regressions in six of seven lines, including those resistant to cyclophosphamide. DTIC had marked activity in five tumors, and mitomycin C in three lines. Cyclophosphamide was active in five tumors, although efficacy was less marked in two lines in comparison to DTIC and mitomycin C.
AB - A laboratory model of childhood rhabdomyosarcoma (RMS) has been used to evaluate cytotoxic agents used in current clinical protocols, and DNA-reacting agents that have had either limited or no evaluation in this histiotype. Seven lines of RMS each derived from a different patient were grown as xenografts in immune-deprived mice, six of these being from specimens derived from previously untreated patients. Of the 'conventional' agents, vincristine was the most effective. Of the other agents evaluated [L-phenylalanine mustard (L-PAM), cis-dichlorodiammineplatinum (cis-DDP), mitomycin C and 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC)], L-PAM caused complete regressions in six of seven lines, including those resistant to cyclophosphamide. DTIC had marked activity in five tumors, and mitomycin C in three lines. Cyclophosphamide was active in five tumors, although efficacy was less marked in two lines in comparison to DTIC and mitomycin C.
UR - http://www.scopus.com/inward/record.url?scp=0021263850&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021263850&partnerID=8YFLogxK
U2 - 10.1016/0277-5379(84)90170-6
DO - 10.1016/0277-5379(84)90170-6
M3 - Article
C2 - 6430707
AN - SCOPUS:0021263850
SN - 0277-5379
VL - 20
SP - 955
EP - 960
JO - European Journal of Cancer and Clinical Oncology
JF - European Journal of Cancer and Clinical Oncology
IS - 7
ER -